Heptamethine cyanine photoacoustic molecule as well as preparation and application thereof
By designing photoacoustic molecules activated by nitro reductase, combining photothermal therapy and photoacoustic imaging technology, the problem of immune system damage and bacterial infection assessment in traditional cancer treatment is solved, and specific imaging and efficient treatment of prostate cancer are achieved, as well as bacterial bacteria Accurate assessment of infection.
Patent Information
- Application Number
- CN202310654007.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-05
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2043-06-05
AI Technical Summary
Existing cancer treatments have problems such as immune system damage, drug resistance and killing of normal cells, and existing optical imaging methods are difficult to quickly and accurately visualize bacterial infections in deep tissues.
A class of photoacoustic molecules activated by nitro reductases were designed to improve the photothermal conversion efficiency by using the light-induced electron transfer mechanism, and to achieve specific targeting of cancer cells and bacteria through prostate-specific targeting groups and neomycin fragments. , used for collaborative photothermal therapy and photodynamic therapy, combined with photoacoustic imaging technology.
It realizes specific photoacoustic imaging and efficient killing of cancer cells in prostate cancer, while also being able to specifically target bacteria for photoacoustic imaging and treatment, providing a more accurate tool for cancer diagnosis and bacterial infection assessment.
Smart Images

Figure CN119080670A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology and relates to a class of heptamethine cyanine molecules used for precise photoacoustic imaging and treatment of cancer and photoacoustic imaging of bacterial infection, and a preparation method and application thereof. Background Art
[0002] Cancer is a major global health problem, with 19.3 million new cases and 10 million cancer-related deaths worldwide in 2020 [1] In order to develop more effective and accurate cancer treatments, researchers around the world have been working to address this challenge. Traditional cancer treatments, such as surgery, radiotherapy and chemotherapy, have disadvantages such as immune system damage, drug resistance and killing of normal cells. [2-5] Therefore, alternative and tolerable cancer treatment strategies are urgently needed. Phototherapy, including photodynamic therapy (PDT) and photothermal therapy (PTT), is a promising cancer treatment method that converts light energy into local hyperthermia to induce heat shock or produces cytotoxic reactive oxygen species (ROS) to ablate cancer cells. [6 -10]. However, as a non-invasive treatment strategy, phototherapy is limited by the limitations of light irradiation, including low toxicity to normal tissues, killing a variety of cells including multidrug-resistant cancers, and stimulating the body's immune response by inducing cell apoptosis or necrosis.
[11] Photosensitizers (PSs) are an important component of phototherapy. Although inorganic materials have excellent photothermal conversion efficiency and photostability, their poor biodegradability and long-term toxicity limit their clinical translation. [1 2 ,13] Therefore, organic photosensitizers with biocompatibility and low cytotoxicity have been developed to improve the efficacy of phototherapy. [6 , 14 - 16] .
[0003] Bacterial infections are also a major medical and public health problem worldwide
[17] Optical imaging is an effective tool for observing and evaluating the pathogenesis and progression of bacteria-related diseases in biomedical research.
[18] However, due to limitations in penetration depth and light scattering, existing optical imaging methods are mainly limited to skin infections. Currently, the most commonly used methods for clinical pneumonia infection imaging include X-rays, CT, and MRI. However, these techniques often lack specificity and have difficulty distinguishing different types of pneumonia infections.
[19] Therefore, rapid, accurate, and real-time molecular imaging strategies are urgently needed to visualize bacteria in deep tissues. Photoacoustic imaging is based on the absorption of pulsed laser light. The absorbed photons release energy in the form of heat, which then vibrate and relax to generate pressure waves, which produce detectable sound waves.
[20] With the development of organic photoacoustic contrast agents, photoacoustic imaging has shown great potential in diagnosing deep tissue bacterial infections as they can provide more specific and sensitive information about the infection site and severity.
[21] .
[0004] Cyanine derivatives have excellent biosafety, high molar extinction coefficients, and deep tissue penetration depths and are considered to be excellent potential candidates for the development of organic photosensitizers and photoacoustic contrast agents. [22-25] Due to the intrinsic targeting of positively charged cyanine derivatives to mitochondria and the sensitivity of mitochondria to heat shock [26-28] The present invention designs and synthesizes a class of nitroreductase (NTR) activated photoacoustic molecules, which utilize the photoinduced electron transfer (PeT) mechanism to improve the photothermal conversion efficiency of PTT, and the incorporation of heavy atoms into cyanine chromophores can effectively promote the intersystem crossing rate and ROS generation of PDT, which is used to synergistically and effectively kill cancer cells. We connected the prostate-specific membrane antigen (PSMA) specific targeting group KUE (Lys-urea-Glu) to the photoacoustic molecule to improve the catalytic activity of NTR, realize prostate cancer (PCa) specific photoacoustic imaging in vivo detection of tumors, and efficiently kill cancer cells through synergistic PTT / PDT. This strategy provides an effective tool for specific diagnosis and phototherapy of cancer. At the same time, we connected the neomycin fragment to the photoacoustic molecule to achieve bacteria-specific targeting, which was used for the first time for the photoacoustic imaging of pneumonia induced by Staphylococcus aureus in situ and tumor-homing bacteria in vivo, and can be used as a visualization tool for evaluating bacterial infection treatment and monitoring bacteria in tumor cells. Summary of the invention
[0005] The technical problem solved by the present invention is to provide a compound or a pharmaceutically acceptable salt thereof, a preparation method thereof and an application thereof.
[0006] In order to solve the technical problem of the present invention, the present invention provides the following technical solutions:
[0007] In a first aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof:
[0008]
[0009] R 1 independently selected from hydrogen atoms and R 2 Independently selected from hydroxyl, and X is independently selected from O, S, and Se.
[0010] Furthermore, the compound of the present invention is selected from:
[0011]
[0012] The second aspect of the technical solution of the present invention is to provide a method for preparing the compound or a pharmaceutically acceptable salt thereof according to the first aspect, characterized in that it comprises the following steps:
[0013]
[0014] Where: R 1 ,R 2 , X is defined as any one of claims 1 to 4;
[0015] (1) adding 4-(Boc-amino)phenol or p-aminothiophenol or 4,4'-diselenanediyldiphenylamine, compound 1, base and solvent to a round-bottom flask, reacting at a set temperature and under stirring conditions, after the reaction is completed, extracting the reaction solution, concentrating under reduced pressure and purifying to obtain I or further reacting with p-nitrobenzyl chloroformate, base and solvent under argon protection under anhydrous conditions at room temperature, extracting the reaction solution after the reaction is completed, concentrating under reduced pressure and purifying to obtain I;
[0016] (2) adding I prepared in step (1), a condensing agent, a base, a ligand and a solvent to a round-bottom flask, reacting at room temperature under argon protection and anhydrous conditions, extracting the reaction solution after the reaction is completed, concentrating and purifying under reduced pressure, and then reacting with trifluoroacetic acid at room temperature, concentrating and purifying under reduced pressure to obtain II; or reacting I prepared in step (1) with di-tert-butyl dicarbonate, a base and a solvent under argon protection and anhydrous conditions at room temperature, extracting the reaction solution after the reaction is completed, concentrating and purifying under reduced pressure, and then reacting the obtained compound with a condensing agent, a base, a ligand and a solvent under argon protection and anhydrous conditions at room temperature, extracting the reaction solution after the reaction is completed, concentrating and purifying under reduced pressure, and then reacting with trifluoroacetic acid at room temperature, concentrating and purifying under reduced pressure to obtain II.
[0017] The third aspect of the technical solution of the present invention is to provide the use of the compound or a pharmaceutically acceptable salt thereof described in the first aspect in the preparation of a photosensitizer.
[0018] The fourth aspect of the technical solution of the present invention is to provide the use of the compound or a pharmaceutically acceptable salt thereof described in the first aspect in the preparation of photoacoustic imaging and therapeutic drugs for prostate cancer at the in vitro, cellular or in vivo levels.
[0019] The fifth aspect of the technical solution of the present invention is to provide the use of the compound or a pharmaceutically acceptable salt thereof described in the first aspect in the preparation of in vitro, cellular or in vivo levels of pneumonia induced by bacteria in situ and photoacoustic imaging of tumor-homing bacteria in vivo, wherein the bacteria is Staphylococcus aureus. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 The absorption and emission spectra of compounds A1-3, B1-3 and C1-4 are shown.
[0021] Figure 2 This indicates that compounds C1 and C3 were reduced by nitroreductase in the presence of β-nicotinamide adenine dinucleotide disodium salt hydrate, and the fluorescence intensity gradually decreased.
[0022] Figure 3 This indicates that compounds B1-3 and C1 have strong ability to produce active oxygen.
[0023] Figure 4 This indicates that compounds A1-3, B1-3, C1 and C2 all have excellent photothermal generation capabilities.
[0024] Figure 5 Compound C1 has obvious phototoxicity and very low dark toxicity to C4-2 cells.
[0025] Figure 6 This indicates that compound C1 significantly inhibits tumor growth after irradiation with light, can be used to treat tumors, and is a good phototherapeutic agent.
[0026] Figure 7 This indicates that compound C3 can be used to specifically target bacteria while having no effect on tumor cells. The photoacoustic signal gradually increases in a time-dependent manner, which can distinguish bacteria from tumors and can be used for photoacoustic imaging of bacteria in tumor tissues. DETAILED DESCRIPTION
[0027] Example 1 Preparation steps of compound A1:
[0028]
[0029] Preparation Example 1, Preparation of Compound 3
[0030] Compound 2 (46.3 mg, 0.22 mmol) was dissolved in ultra-dry N,N-dimethylformamide (1.5 mL), and sodium hydride (60% dispersed in mineral oil, 7.1 mg, 0.30 mmol) was slowly added under argon protection at 0°C. After stirring at room temperature for 10 minutes, compound 1 (100 mg, 0.15 mmol) was added to the above system, and the reaction system was stirred at 40°C for 3 hours. After the reaction was completed, the reaction system was diluted with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by medium pressure column chromatography (4% MeOH / CH 2 Cl 2 ), compound 3 was obtained as a green solid, 73.5 mg, with a yield of 58.6%.
[0031] Preparation Example 2, Preparation of Compound A1
[0032] Compound 3 (55.0 mg, 0.065 mmol) was added to trifluoroacetic acid and stirred at room temperature for 20 minutes. The reaction system was diluted with dichloromethane and concentrated under reduced pressure. This process was repeated five times to remove trifluoroacetic acid. The residue was purified by medium pressure column chromatography (5% MeOH / CH 2 Cl 2 ), compound A1 was obtained as a blue-black solid, 43.7 mg, with a yield of 90.1%. 1 H NMR (600MHz, CD 3 OD-d 4 ): δ8.05(dd,J=14.2,8.5Hz,2H),7.40-7.36(m,4H),7.25(dd,J=8.0,4.7Hz,2H),7.21(q,J=7.1 Hz,2H),6.90(d,J=8.6Hz,2H),6.76(d,J=8.7Hz,2H),6.13(dd,J=14.2,7.7Hz,2H),4.13(q,J=7 .2Hz,2H),4.09(t,J=7.5Hz,2H),2.73(t,J=6.3Hz,4H),2.30(t,J=7.3Hz,2H),2.05-2.01(m,2H ),1.83-1.79(m,2H),1.71-1.66(m,2H),1.50-1.44(m,2H),1.39(s,12H),1.36(t,J=7.3Hz,3H). 13 C NMR (150MHz, CD 3 OD-d 4): δ177.63,173.50,173.29,166.52,154.85,143.93,143.61,143.16,142.64,1 42.46,129.77,129.73,126.13,126.03,123.57,123.52,123.41,123.37,118.26 ,116.22,111.84,111.64,100.64,100.40,50.29,50.24,44.79,40.01,34.91,28 .24,28.13,27.94,27.39,25.78,25.27,25.21,22.51,12.31.HRMS(ESI)m / z:[M] + The theoretical value is C 44 H 52 N 3 O 3 + ,670.4003; the measured value is 670.3999.
[0033] Example 2 Preparation steps of compound A2:
[0034]
[0035] Preparation Example 3, Preparation of Compound A2
[0036] Compound 1 (100 mg, 0.15 mmol) was dissolved in ultra-dry N,N-dimethylformamide (1.5 mL), and compound 4 (92.3 mg, 0.74 mmol) was added under argon protection. After stirring at room temperature for 2 hours, the reaction system was diluted with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by medium pressure column chromatography (4% MeOH / CH 2 Cl 2 ), compound A2 was obtained as a blue-black solid, 75 mg, with a yield of 74%. 1 H NMR (400MHz, CD 3 OD-d 4): δ8.72(dd,J=13.9,8.3Hz,2H),7.43–7.40(m,3H),7.38-7.35(m,3H), 7.29-7.27(m,3H),7.25-7.20(m,3H),6.29(dd,J=13.6,10.2Hz,2H),4.1 9-4.11(m,4H),2.78(s,4H),2.29(t,J=7.1Hz,2H),2.03–2.00(m,2H),1. 83–1.78(m,2H),1.70-1.63(m,2H),1.46(s,14H),1.36(t,J=6.7Hz,3H). 13 C NMR (100 MHz, DMSO-d 6 ): δ174.28,171.72,171.55,150.49,145.34,144.99,142.07,141.61,141.19,140 .99,133.16,133.08,128.54,128.50,127.53,124.96,124.85,122.40,122.35,11 8.94,111.27,111.14,101.48,101.41,59.72,48.79,48.71,43.49,33.47,27.27, 27.16,26.65,25.79,25.65,24.15,20.72,20.42,14.04,12.16.HRMS(ESI)m / z:[M] + The theoretical value is C 44 H 52 N 3 O 2 S + ,686.3775; the measured value is 686.3771.
[0037] Example 3 Preparation steps of compound A3:
[0038]
[0039] Preparation Example 4, Preparation of Compound A3
[0040] Compound 5 (280.3 mg, 0.82 mmol) was dissolved in ethanol (16 mL), and sodium borohydride (108.5 mg, 2.87 mmol) was added in batches under argon protection at 0°C. After stirring at 0°C for 15 minutes, citric acid was added to the reaction system, and the reaction was continued at 0°C for 10 minutes. Then, a solution of compound 1 (1 g, 1.48 mmol) in ultra-dry N,N-dimethylformamide (24 mL) was added to the above reaction system, and stirred at room temperature for 2 hours. After the reaction was completed, the reaction system was diluted with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by medium pressure column chromatography (5% MeOH / CH 2 Cl 2 ), compound A3 was obtained as a blue-black solid, 524 mg, with a yield of 78.6%. 1 H NMR (500MHz, CD 3 OD-d 4 ): δ8.85-8.80(m,2H),7.47(d,J=8.7Hz,2H),7.44(t,J=6.3Hz,2H),7.41-7.38(m,2H),7.2 9(t,J=7.9Hz,2H),7.28-7.23(m,4H),6.30(dd,J=14.2,11.0Hz,2H),4.19(q,J=7.1Hz,2H) ,4.15(t,J=7.4Hz,2H),2.81(t,J=7.3Hz,4H),2.31(t,J=7.3Hz,2H),2.07-2.02(m,2H),1. 87-1.81(m,2H),1.72-1.66(m,2H),1.52(s,12H),1.51-1.46(m,2H),1.39(t,J=7.2Hz,3H). 13 C NMR (150MHz, CD 3 OD-d 4 ): δ177.21,173.98,173.84,155.34,150.80,150.38,143.62,143.12,142.76,142.5 6,135.30,135.20,131.07,129.87,129.83,126.47,126.34,123.48,123.43,122.64 ,122.56,112.09,111.94,102.40,102.26,50.55,50.47,44.93,40.22,34.60,31.13 ,28.14,28.06,28.03,27.75,27.70,27.36,25.65,22.33,12.45.HRMS(ESI)m / z:[M]+ The theoretical value is C 44 H 52 N 3 O 2 Se + ,734.3219; the measured value is 734.3220.
[0041] Example 4 Preparation steps of compound B1-3:
[0042]
[0043] Preparation Example 5, Preparation of Compound B1
[0044] Compound A1 (50 mg, 0.075 mmol) and compound 6 (24.1 mg, 0.11 mmol) were dissolved in ultra-dry dichloromethane (0.75 mL), and N,N-diisopropylethylamine (13 μL, 0.11 mmol) was added to the system under argon protection. The reaction was completed after stirring at room temperature for 30 minutes. The reaction system was diluted with dichloromethane, washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by medium pressure column chromatography (4% MeOH / CH 2 Cl 2 ), compound B1 was obtained as a green solid, 31.6 mg, with a yield of 49.9%. 1 H NMR (600 MHz, CDCl 3 ): δ9.13(s,1H),8.15(d,J=8.3Hz,2H),7.92(d,J=14.0Hz,2H),7.70(d,J=8.5Hz,2H),7.59(d,J=8.3Hz,2H),7.33(q,J= 7.6Hz,2H),7.25(s,2H),7.18(q,J=7.3Hz,2H),7.05(d,J=8.0Hz,1H),7.01(d,J=7.9Hz,1H),6.96(d,J=8.6Hz,2H),5.9 8(d,J=14.4Hz,1H),5.88(d,J=14.0Hz,1H),5.24(s,2H),4.00-3.96(m,4H),2.69(t,J=6.2Hz,2H),2.65(t,J=6.2Hz,2H ),2.46(t,J=7.1Hz,2H),2.05-2.01(m,2H),1.80-1.75(m,2H),1.67-1.63(m,2H),1.38(t,J=7.2Hz,3H),1.33(s,14H). 1 3C NMR (150MHz, CDCl 3): δ172.80,171.29,165.41,155.89,154.04,147.51,144.58,143.12,142.26,142.18,141.78,1 41.19,140.96,134.00,128.90,128.86,128.72,128.03,125.52,125.08,123.79,122.78,122.5 3,122.46,122.36,121.28,114.78,110.80,109.94,100.01,98.74,64.96,49.55,49.13,44.75, 39.22,34.50,29.84,28.01,27.97,27.06,26.25,24.59,24.46,21.21,12.24.HRMS(ESI)m / z:[M] + The theoretical value is C 52 H 57 N 4 O 7 + ,849.4222; the measured value is 849.4193.
[0045] Preparation Example 6, Preparation of Compound B2
[0046] Compound A2 (75 mg, 0.11 mmol) and compound 6 (35.3 mg, 0.16 mmol) were dissolved in ultra-dry dichloromethane (1.1 mL), and N,N-diisopropylethylamine (28.5 μL, 0.16 mmol) was added to the system under argon protection. The reaction was completed after stirring at room temperature for 5 minutes. The reaction system was diluted with dichloromethane, washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by medium pressure column chromatography (4% MeOH / CH 2 Cl 2 ) to obtain compound B2 as a gray-green solid, 27.5 mg, with a yield of 29.1%. 1 H NMR (600 MHz, CDCl 3): δ8.76(d,J=43.6Hz,2H),8.13(d,J=8.8Hz,2H),7.53(d,J=8.8Hz,4H),7.35(t,J=7.7Hz ,2H),7.30(t,J=6.3Hz,2H),7.21(s,2H),7.10(d,J=8.8Hz,2H),7.08-7.03(m,2H),6.08(d ,J=47.9Hz,2H),5.20(s,2H),4.02(s,4H),2.68(s,4H),2.36(t,J=7.2Hz,2H),2.02-1.99( m,2H),1.83-1.80(m,2H),1.67-1.62(m,2H),1.50(s,6H),1.46(s,6H),1.42-1.37(m,5H). 13 CNMR (150MHz, CDCl 3 ): δ173.28,171.67,153.75,153.66,147.53,147.42,146.27,144.33,142.10,141.83,141.31,1 41.23,137.15,134.31,133.81,130.44,128.92,128.78,128.04,126.92,125.65,125.19,123.7 7,122.52,122.45,120.34,110.93,110.11,101.60,100.25,65.05,49.66,49.31,44.62,39.31, 34.20,31.37,28.06,28.04,27.18,26.48,26.44,26.30,24.50,20.87,12.29.HRMS(ESI)m / z:[M] + The theoretical value is C 52 H 57 N 4 O 6 S + ,865.3993; the measured value is 865.3995.
[0047] Preparation Example 7, Preparation of Compound B3
[0048] Compound A3 (500 mg, 0.68 mmol) and compound 6 (220 mg, 1.02 mmol) were dissolved in ultra-dry dichloromethane (6.8 mL), and N,N-diisopropylethylamine (128 μL, 1.02 mmol) was added to the system under argon protection. The reaction was completed after stirring at room temperature for 30 minutes. The reaction system was diluted with dichloromethane, washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by medium pressure column chromatography (6% MeOH / CH 2 Cl 2 ), compound B3 was obtained as a gray-green solid, 226 mg, with a yield of 32.0%. 1 H NMR (600 MHz, CDCl 3 ): δ8.78(s,2H),8.13(d,J=8.0Hz,2H),7.53(d,J=7.2Hz,4H),7.36(s,2H) ,7.31(t,J=6.0Hz,2H),7.22-7.17(m,4H),7.06(d,J=23.6Hz,2H),6.10(d ,J=56.3Hz,2H),5.20(s,2H),4.04(s,4H),2.73(s,4H),2.39(s,2H),2.01 (s,2H),1.85(s,2H),1.66(s,2H),1.54(s,6H),1.49(s,6H),1.43(s,5H). 13 CNMR (150MHz, CDCl 3 ): δ173.40,171.58,156.64,153.72,150.61,149.18,147.54,144.32,142.07,141.87,141 .27,137.71,134.81,134.45,129.29,128.95,128.80,128.12,125.68,125.16,123.81,12 2.57,122.50,120.69,111.05,110.15,101.90,100.39,65.10,49.66,49.30,44.88,39.71 ,34.32,31.37,29.84,28.09,27.30,27.19,26.40,24.61,21.20,12.52.HRMS(ESI)m / z:[M] + The theoretical value is C 52 H 57 N 4 O 6 Se + ,913.3438; the measured value is 913.3439.
[0049] Example 5 Preparation steps of compound C1:
[0050]
[0051] Preparation Example 8, Preparation of Compound 9
[0052] Compound 7 (180 mg, 0.28 mmol) and compound 8 (122.8 mg, 0.25 mmol) were dissolved in ultra-dry tetrahydrofuran (2.5 mL), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (143.6 mg, 0.38 mmol) and N,N-diisopropylethylamine (87.8 μL, 0.50 mmol) were added, and the system was stirred at room temperature for 2 hours under argon protection. After the reaction was completed, the reaction solvent was distilled under reduced pressure, the residue was dissolved in dichloromethane, washed with water, and dried over anhydrous sodium sulfate. The residue was purified by medium pressure column chromatography (4% MeOH / CH 2 Cl 2 ) to obtain compound 9 as a colorless oil, 271 mg, with a yield of 96.1%.
[0053] Preparation Example 9, Preparation of Compound 10
[0054] Compound 9 (271 mg, 0.24 mmol) was dissolved in acetonitrile (7.5 mL), and diethylamine (2.5 mL, 24.21 mmol) was added. The mixture was reacted at room temperature for 40 minutes under argon protection. After the reaction was completed, the reaction solvent was distilled off under reduced pressure, and the residue was purified by medium pressure column chromatography (10% MeOH / CH 2 Cl 2 ), compound 10 was obtained as a colorless oil, 64 mg, with a yield of 29.5%. 1 H NMR (400 MHz, CDCl 3 ): δ7.87(s,2H),7.61(s,1H),4.33(dd,J=8.8,4.9Hz,1H),4.23(dd,J=7.7, 4.4Hz,1H),4.07(s,2H),3.89(s,2H),3.74-3.65(m,28H),3.29(s,2H),3.1 9(s,2H),2.41-2.27(m,2H),2.10-2.00(m,1H),1.89-1.82(m,1H),1.80-1. 67(m,2H),1.60-1.51(m,2H),1.44(s,18H),1.42(s,9H),1.32-1.20(m,2H). 13 C NMR (150 MHz, CDCl 3): δ172.79,172.68,172.46,170.52,157.69,81.60,81.30,80.46,70.88,70.67,70.52,70.44,70.40,70.32,70.28,70.19 ,70.16,70.03,67.05,53.78,53.02,40.69,38.32,31.90,31.83,29.11,28.55,28.24,28.18,22.51.HRMS(ESI)m / z:[M+H] + The theoretical value is C 42 H 81 N 4 O 16 + ,897.5642; the measured value is 897.5631.
[0055] Preparation Example 10, Preparation of Compound C1
[0056] Compound B3 (24.4 mg, 0.026 mmol) was dissolved in ultra-dry dichloromethane (1 mL), and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (6.2 mg, 0.032 mmol), 1-hydroxybenzotriazole (4.3 mg, 0.032 mmol) and N,N-diisopropylethylamine (5.6 μL, 0.032 mmol) were added under argon protection. After reacting at room temperature for 20 minutes, compound 10 (24 mg, 0.026 mmol) was added to the above system, and the reaction was continued at room temperature for 4 hours. After the reaction was completed, the reaction system was diluted with dichloromethane, washed with water, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and used directly in the next step without further purification.
[0057] The above residue (40 mg, 0.022 mmol) and triethylsilane (64 μL, 0.402 mmol) were dissolved in dichloromethane (440 μL), trifluoroacetic acid (410 μL, 5.357 mmol) was slowly added dropwise, and the reaction system was stirred at room temperature for 11 hours. After the reaction was completed, the reaction system was diluted with dichloromethane and concentrated under reduced pressure, and the trifluoroacetic acid was removed by repeating five times. The residue was purified by high performance liquid chromatography to obtain compound C1 as a gray-green solid, 12 mg, and the total yield of the two steps was 27.7%. 1 H NMR (600 MHz, DMSO-d 6):δ12.49(s,3H),9.89(s,1H),8.70(dd,J=14.1,3.0Hz,2H),8.22(d,J=8.7Hz,2H),7.82(t,J=5.7Hz,1H),7.66(t,J=5.9Hz,1H),7.63(d,J=8.6Hz,2H),7.54(dd,J=7.4,4.9Hz,2H),7.41-7.38(m,6H),7.28(d,J=8.8Hz,2H),7.25-7.22(m,2H),6.33-6.28(m,4H),5.24(s,2H),4.21(q,J=7.2Hz,2H),4.15(t,J=7.5Hz,2H),4.10(td,J=8.3,5.2Hz,1H),4.04(td,J=8.1,5.2Hz,1H),3.84(s,2H),3.55(s,4H),3.52(s,4H),3.50-3.48(m,22H),3.16(q,J=5.9Hz,2H),3.07(q,J=6.9Hz,2H),2.75(q,J=6.3Hz,4H),2.29-2.18(m,2H),2.06(t,J=7.3Hz,2H),2.02-1.96(m,1H),1.94-1.89(m,3H),1.74-1.67(m,3H),1.66-1.61(m,1H),1.57-1.52(m,4H),1.48(s,12H),1.43-1.38(m,2H),1.37-1.32(m,2H),1.28(t,J=7.1Hz,3H). 13 C NMR(150MHz,DMSO-d 6): δ174.51,174.14,173.71,171.95,171.80,171.57,168.99,157.25,152.94,152.92,148.43,148.13,147.05,144.42,142.07,141.6 3,141.20,141.02,137.51,133.59,133.55,129.65,128.97,128.57,128.52,128.44,124.96,124.88,124.75,123.58,122.47,122.41 ,119.67,111.29,111.14,101.53,101.39,70.22,69.93,69.76,69.71,69.56,69.51,69.15,64.52,52.26,51.62,48.81,48.74,43.55 ,38.41,37.93,34.99,31.78,29.88,28.91,27.55,27.19,27.09,26.71,26.22,25.76,24.85,22.56,20.63,12.19.HRMS(ESI)m / z:[M] + The theoretical value is C 82 H 111 N 8 O 21 Se + ,1623.7024; the measured value is 1623.7024.
[0058] Example 6 Preparation steps of compound C2:
[0059]
[0060] Preparation Example 11, Preparation of Compound 11
[0061] Compound A3 (50 mg, 0.068 mmol) was dissolved in ethanol (1.6 mL), and di-tert-butyl dicarbonate (18.8 μL, 0.082 mmol) was added under argon protection. After reacting at room temperature for 12 hours, the solvent was removed by distillation under reduced pressure, and the residue was dissolved in dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by medium pressure column chromatography (6% MeOH / CH 2 Cl 2 ), compound 11 was obtained as a gray-green solid, 35.1 mg, with a yield of 56.5%. 1 H NMR (600 MHz, CDCl 3): δ8.79(dd,J=23.3,13.8Hz,2H),7.38-7.30(m,6H),7.22(t,J=7.4Hz,1H),7.21-7.18(m,3H),7.11(d,J=8 .0Hz,1H),7.05(d,J=7.9Hz,1H),6.99(s,1H),6.19(d,J=14.1Hz,1H),6.05(d,J=13.9Hz,1H),4.05-4.02(m ,4H),2.71(dt,J=21.1,5.9Hz,4H),2.47(t,J=6.7Hz,2H),2.02-1.99(m,2H),1.86-1.81(m,2H),1.76-1.71 (m,2H),1.54(s,6H),1.52(s,6H),1.50-1.48(m,2H),1.45(s,9H),1.41(t,J=7.0Hz,3H).HRMS(ESI)m / z:[M] + The theoretical value is C 49 H 60 N 3 O 4 Se + ,834.3744; the measured value is 834.3740.
[0062] Preparation Example 12, Preparation of Compound C2
[0063] Compound 11 (28.6 mg, 0.034 mmol) was dissolved in ultra-dry dichloromethane (1.4 mL), and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (7.2 mg, 0.037 mmol), 1-hydroxybenzotriazole (5.1 mg, 0.037 mmol) and N,N-diisopropylethylamine (6.5 μL, 0.037 mmol) were added under argon protection. After reacting at room temperature for 20 minutes, compound 10 (28 mg, 0.031 mmol) was added to the above system, and the reaction was continued at room temperature for 5 hours. After the reaction was completed, the reaction system was diluted with dichloromethane, washed with water, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and used directly in the next step without further purification.
[0064] The above residue (45.8 mg, 0.027 mmol) and triethylsilane (77 μL, 0.481 mmol) were dissolved in dichloromethane (540 μL), trifluoroacetic acid (637 μL, 6.416 mmol) was slowly added dropwise, and the reaction system was stirred at room temperature for 4 hours. After the reaction was completed, the reaction system was diluted with dichloromethane and concentrated under reduced pressure, and the trifluoroacetic acid was removed by repeating five times. The residue was purified by high performance liquid chromatography to obtain compound C2 as a gray-green solid, 14.3 mg, and the total yield of the two steps was 30.1%.1 H NMR(600MHz,DMSO-d 6 ):δ8.76(dd,J=14.1,5.5Hz,2H),7.82(t,J=5.7Hz,1H),7.66(t,J=5.9Hz,1H),7.56(dd,J=7.4,5.0Hz,2H),7.41-7.38(m,4H),7.26-7.23(m,2H),7.12(d,J=8.6Hz,2H),6.63(d,J=7.9Hz,2H),6.3-6.27(m,4H),4.21(q,J=7.3,6.8Hz,2H),4.15(t,J=7.4Hz,2H),4.10(td,J=8.3,5.2Hz,1H),4.04(td,J=8.0,5.2Hz,1H),3.85(s,2H),3.55(s,4H),3.52(s,4H),3.50-3.49(m,22H),3.16(q,J=5.9Hz,2H),3.07(q,J=6.8Hz,2H),2.72(q,J=6.5Hz,4H),2.29-2.18(m,2H),2.07(t,J=7.3Hz,2H),2.02-1.85(m,4H),1.74-1.67(m,3H),1.66-1.61(m,1H),1.57-1.50(m,16H),1.43-1.38(m,2H),1.37-1.34(m,2H),1.29(t,J=7.2Hz,3H). 13 C NMR(150MHz,DMSO-d 6): δ174.51,174.14,173.71,171.96,171.74,171.51,168.99,157.26,154.48,148.69,148.40,142.11,141.66,141.19 ,141.01,133.58,133.51,130.05,129.65,128.57,128.52,124.92,124.84,122.45,122.40,117.05,111.25,111.09,10 1.43,101.28,70.23,69.93,69.77,69.71,69.57,69.51,69.15,52.27,51.63,48.81,48.75,43.52,38.41,37.93,34.99 ,31.78,31.30,29.88,28.91,27.55,27.26,27.16,26.69,26.21,25.77,24.86,22.56,20.68,12.17.HRMS(ESI)m / z:[M] + The theoretical value is C 74 H 106 N 7 O 17 Se + ,1444.6805; the measured value is 1444.6814.
[0065] Example 7 Preparation steps of compound C3:
[0066]
[0067] Preparation Example 13, Preparation of Compound C3
[0068] Compound B1 (13 mg, 0.015 mmol) was dissolved in ultra-dry dichloromethane (1.2 mL), and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (8.63 mg, 0.045 mmol), 1-hydroxybenzotriazole (6.08 mg, 0.045 mmol) and N,N-diisopropylethylamine (5.8 mg, 0.045 mmol) were added under argon protection. After reacting at room temperature for 30 minutes, compound 12 (22 mg, 0.018 mmol) was added to the above system, and the reaction was continued at room temperature for 2 hours. After the reaction was completed, the reaction system was diluted with dichloromethane, washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and used directly in the next step without further purification.
[0069] The above residue was dissolved in trifluoroacetic acid (600 μL), and the reaction system was stirred at room temperature for 15 minutes. After the reaction was completed, the reaction system was diluted with dichloromethane and concentrated under reduced pressure, and the trifluoroacetic acid was removed by repeating five times. The residue was purified by high performance liquid chromatography to obtain compound C3 as a green solid, 19 mg, and the total yield of the two steps was 85.9%. 1 H NMR (400 MHz, DMSO-d 6 )δ9.86(s,1H),8.34(s,6H),8.25(d,J=8.5Hz,2H),8.20-8.10(m,6H),8.06(s,6H),7.91-7.76(m,6 H),7.67(d,J=8.5Hz,3H),7.56-7.46(m,4H),7.43-7.38(m,2H),7.36(d,J=7.8Hz,1H),7.29(d,J=8. 1Hz,1H),7.26-7.22(m,1H),7.19(t,J=7.4Hz,1H),7.11(d,J=9.0Hz,2H),6.22(d,J=14.3Hz,1H),6. 12(d,J=14.1Hz,1H),5.77-5.66(m,1H),5.26(s,2H),5.21(s,1H),5.02(s,1H),4.27-4.23(m,1H),4 .22-4.16(m,2H),4.15-4.07(m,4H),4.06-3.99(m,3H),3.97-3.88(m,3H),3.78(t,J=8.8Hz,1H),3 .55(s,1H),3.50(d,J=7.9Hz,1H),3.43(t,J=9.4Hz,1H),3.38-3.30(m,1H),3.29-3.19(m,6H),3.13 (s,3H),3.02(s,1H),2.77-2.62(m,4H),2.36(s,1H),2.23-2.11(m,2H),1.93(s,2H),1.81-1.70(m, 2H),1.70-1.62(m,2H),1.59-1.52(m,2H),1.38(dd,J=13.4,7.5Hz,2H),1.30(s,12H),1.26(s,3H); 13 C NMR (100 MHz, DMSO-d 6)δ173.57,171.66,170.87,162.79,158.80,158.47,155.08,153.11, 147.05,144.56,142.05,141.52,141.39,141.15,140.81,140.31,133 .43,128.56,128.44,128.34,125.03,124.56,123.59,122.49,121.56 ,121.43,120.86,120.16,117.88,115.18,114.95,114.56,111.18,11 0.81,108.49,100.30,99.56,95.52,93.67,84.12,80.01,77.81,73.57,72.35,70.92,70.69,70.09,67.86,67.32,66.87,64.45,53.40,51.08,49.41,48.74,48.63,48.38,43.37,40.99,35.20,27.98,27.28,27.08,26.70,26.11,24.95,23.67,20.66,12.14. HRMS (ESI): m / z theoretical value is C 75 H 102 N 11 O 18 + :1444.7399[M] + ; The measured value is 1444.7421.
[0070] Example 8 Preparation steps of compound C4:
[0071]
[0072] Preparation Example 14, Preparation of Compound C4
[0073] Compound 3 (19 mg, 0.0248 mmol) was dissolved in ultra-dry dichloromethane (0.33 mL), and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (6.3 mg, 0.033 mmol), 1-hydroxybenzotriazole (4.5 mg, 0.033 mmol) and N,N-diisopropylethylamine (4.3 mg, 0.033 mmol) were added under argon protection. After reacting at room temperature for 30 minutes, compound 12 (20 mg, 0.0165 mmol) was added to the above system, and the reaction was continued at room temperature for 2 hours. After the reaction was completed, the reaction system was diluted with dichloromethane, washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and used directly in the next step without further purification.
[0074] The above residue was dissolved in trifluoroacetic acid (760 μL), and the reaction system was stirred at room temperature for 15 minutes. After the reaction was completed, the reaction system was diluted with dichloromethane and concentrated under reduced pressure, and the trifluoroacetic acid was removed by repeating five times. The residue was purified by high performance liquid chromatography to obtain compound C4 as a green solid, 14.1 mg, and the total yield of the two steps was 44%. 1 H NMR (400 MHz, DMSO-d 6 )δ8.11–7.98(m,2H),7.40(dd,J=7.8,2.8Hz,2H),7.38-7.34(m,2H),7.29-7.24(m,1H),7.22(d ,J=3.9Hz,1H),7.21-7.16(m,2H),6.90(d,J=2.0Hz,1H),6.89(s,1H),6.78(s,1H),6.76(s,1H), 6.12(dd,J=23.7,14.2Hz,2H),5.66(d,J=3.4Hz,1H),5.36(d,J=5.3Hz,1H),5.29(s,1H),4.43- 4.36(m,1H),4.31-4.24(m,1H),4.23-4.18(m,1H),4.16(s,1H),4.15-4.11(m,2H),4.09(d,J=6. 9Hz,2H),4.07-4.01(m,2H),3.90-3.83(m,1H),3.76(s,2H),3.70(d,J=2.5Hz,1H),3.66(s,3H) ,3.62-3.53(m,2H),3.41(s,2H),3.40-3.36(m,2H),3.35(s,1H),3.25-3.21(m,1H),3.20-3.03( m,4H),2.80-2.68(m,4H),2.32-2.20(m,3H),2.08-1.95(m,3H),1.85-1.75(m,2H),1.74-1.60(m ,4H),1.51-1.42(m,3H),1.39(s,9H),1.36(s,3H),1.34(s,2H),1.29(s,2H),1.25-1.20(m,2H). 13 CNMR (100MHz, DMSO-d 6)δ176.69,173.61,173.10,166.47,154.83,144.24,143.70,143.56,143.29,143.08,142.68,142.39,129.79,12 9.70,126.27,125.90,123.52,123.49,123.43,123.38,118.28,116.20,111.80,111.69,100.66,100.34,97.35,8 3.26,80.48,77.97,75.66,74.70,73.28,72.15,70.97,70.65,69.31,55.69,52.95,51.59,50.39,50.13,44.82,41.96,41.87,41.71,40.09,36.91,28.28,28.10,27.77,26.70,25.27,25.18,22.51,12.36. HRMS (ESI): m / z theoretical value is C 67 H 97 N 10 O 14 + :1265.7180[M] + ; The measured value is 1265.7253.
[0075] Pharmacological experiments
[0076] Experimental Example 1: Absorption and emission spectra of compounds A1-3, B1-3 and C1-4
[0077] Compounds A1-3, B1-3 and C1-4 were dissolved in dimethyl sulfoxide, and the absorption and normal emission spectra of the compounds were measured by an ELISA reader. Figure 1 .
[0078] Experimental Example 2: Compound C1 and C3 reduction experiment by nitroreductase
[0079] Compound C1 was dissolved in 0.05M tris(hydroxymethylaminomethane) solution (pH=7.4, containing 1.5% dimethyl sulfoxide), β-nicotinamide adenine dinucleotide disodium salt hydrate (500μM) and nitroreductase (10μg / mL) were added in sequence, and the emission spectrum of the compound was immediately monitored (excitation wavelength 740nm). Compound C1 (5μM) was immediately reduced by nitroreductase (10μg / mL), and the fluorescence intensity gradually decreased with the extension of incubation time. Figure 2 .
[0080] Compound C3 was dissolved in 0.05M tris(hydroxymethylaminomethane) solution (pH=7.4, containing 1.5% dimethyl sulfoxide), β-nicotinamide adenine dinucleotide disodium salt hydrate (500μM) and nitroreductase (2μg / mL) were added in sequence, and the emission spectrum of the compound was immediately monitored (excitation wavelength 740nm). Compound C3 (10μM) was immediately reduced by nitroreductase (2μg / mL), and the fluorescence intensity gradually decreased with the extension of incubation time, which could reach 6 times. Figure 2 .
[0081] Experimental Example 3: Active oxygen generation ability of compounds A1-3, B1-3 and C1-2
[0082] 2',7'-Dichlorodihydrofluorescein diacetate (DCFH-DA) was used as an indicator of reactive oxygen species. First, a DCFH-DA solution (0.5 mL, 1 mM dissolved in ethanol) was mixed with a sodium hydroxide solution (2 mL, 10 mM dissolved in water), stirred at room temperature for 30 minutes, and then diluted with phosphate buffer (1x, pH 7.4) to a final concentration of 40 μM. Compounds A1-3, B1-3, and C1-2 (1 μL, 5 mM) were added to the DCFH solution to obtain a compound concentration of 10 μM. Under a 785 nm laser (200 mW / cm 2 ,1min) irradiation, the fluorescence emission spectrum under 480nm excitation was measured every 10 seconds. Compounds B1-3 and C1 both have strong ability to generate active oxygen. Figure 3 .
[0083] Experimental Example 4: Photothermal property determination of compounds A1-3, B1-3 and C1-2
[0084] The compound was diluted with dimethyl sulfoxide to a final concentration of 20 μM and irradiated with a 785 nm laser (800 mW / cm 2 ,7min). At the same time, the solution temperature was recorded every 30s using an infrared thermal imager. The results showed that compounds A1-3, B1-3 and C1-2 all had strong photothermal generation capabilities, among which compounds A1-3 and C2 had strong photothermal generation capabilities under 785nm laser (800mW / cm 2 ) for 7 minutes, the temperature increased by 16.7, 17.4, 14.3 and 15.5°C respectively. Figure 4
[0085] Experimental Example 5: Phototoxicity and dark toxicity determination of compound C1
[0086] The cell viability was determined by CCK-8 assay. 4 cells / mL, 100 μL) were inoculated in a 96-well plate and incubated at 37°C and 5% CO 2 , normoxia (21% O2 ) or hypoxia (1% O 2 ) for 24 h. For the phototoxicity experiment, the cells were treated with compound C1 at concentrations of 2.5 μM, 5 μM, 10 μM, and 20 μM, respectively, at 37°C and 5% CO 2 After culturing for 2 h under normoxic and hypoxic conditions, the cells were illuminated with 808 nm laser (800 mW / cm 2 ) for 5 minutes, and then continued to culture for 22 hours under normoxic and hypoxic conditions. For dark toxicity, the cells were treated with compound C1 at concentrations of 2.5 μM, 5 μM, 10 μM, and 20 μM, respectively, at 37°C and 5% CO 2 The cells were cultured under normoxic and hypoxic conditions for 24 h, respectively. 20 μL CCK8 was added to each well, and then incubated at 37°C and 5% CO 2 After 1 hour of incubation, the absorbance OD value of each group was measured on an ELISA instrument with a wavelength set to 450nm. According to the OD value of each well, the cell survival rate was calculated by the formula. The formula is as follows: Cell survival rate (%) = (experimental group OD / control group OD) × 100%. Compound C1 has obvious phototoxicity to C4-2 cells and very low dark toxicity. Figure 5 .
[0087] Experimental Example 6: Phototherapeutic effect of compound C1 on C4-2 tumor-bearing mice.
[0088] BALB / c-nude male mice aged 6-8 weeks and weighing an average of 20 g were injected subcutaneously in the left upper limb shoulder with C4-2 cell suspension (200 μL, approximately 2×10 6 cells). The mice were divided into 4 groups: (1) saline group; (2) saline + light group; (3) compound C1 group; (4) compound C1 + light group. When the tumor volume grew to 60-200 mm 3 Afterwards, compound C1 (20 μM, 50 μL) or saline (50 μL) was injected into the tumor. One hour later, the tumor was illuminated with a 785 nm laser (800 mW / cm 2 ) irradiated the tumor area for 5 minutes, then measured the mouse weight and tumor volume, and administered once every three days for 18 days. Tumor volume = 1 / 2 × length × width × height. The results showed that compound C1 significantly inhibited tumor growth after illumination, and can be used to treat tumors, and is a good phototherapy agent. Figure 6 .
[0089] Experimental Example 7: Compound C3 is used for photoacoustic imaging of bacteria in tumor tissue.
[0090] BALB / c-nude male mice aged 6-8 weeks and weighing an average of 20 g were injected subcutaneously at the end of the left hind limb with PANC1 cell suspension (approximately 5-6×10 7 cells), with tumor volume growing to 500mm3 , intratumoral injection of Staphylococcus aureus (1×10 9 CFU), followed by intratumoral injection of compound C3 (100μL, 20μM). Small animal photoacoustic imaging monitoring (excitation wavelength 785nm) was performed at 0.5h and 2h, respectively. The results showed that compound C3 can be used to specifically target bacteria without affecting tumor cells. The photoacoustic signal gradually increased in a time-dependent manner, which can distinguish bacteria from tumors and can be used for photoacoustic imaging of bacteria in tumor tissues. Figure 7 .
[0091] References
[0092] [1]SUNG H,FERLAY J,SIEGEL RL,et al.Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36Cancers in185Countries[J].CACancer J Clin,2021,71(3):209-49.
[0093] [2]CHEN
[0094] [3]GALLETTI G,LEACH BI,LAM L,et al.Mechanisms of resistance tosystemic therapy in metastatic castration-resistant prostate cancer[J].CancerTreat Rev,2017,57:16-27.
[0095] [4]MARTINI A,GANDAGLIAG,FOSSATI N,et al.Defining ClinicallyMeaningful Positive Surgical Margins in Patients Undergoing RadicalProstatectomy for Localised Prostate Cancer[J].Eur Urol Oncol,2021,4(1):42-8.
[0096] [5]VOZENIN M C,BOURHIS J,DURANTE M.Towards clinical translation ofFLASH radiotherapy[J].Nat Rev Clin Oncol,2022,19(12):791-803.
[0097] [6]LI K,XU S,XIONG M,et al.Molecular engineering of organic-basedagents for in situ bioimaging and phototherapeutics[J].Chem Soc Rev,2021,50(21):11766-84.
[0098] [7]XIE Z,FAN T,AN J,et al.Emerging combination strategies withphototherapy in cancer nanomedicine[J].Chem Soc Rev,2020,49(22):8065-87.
[0099] [8]XU C,YE R,SHEN H,et al.Molecular Motion and Nonradiative Decay:Towards Efficient Photothermal and Photoacoustic Systems[J].Angew Chem Int EdEngl,2022,61(30):e202204604.
[0100] [9]ZHANG J,NING L,HUANG J,et al.Activatable molecular agents forcancer theranostics[J].Chem Sci,2019,11(3):618-30.
[0101]
[10] ZHAO H,LI N,MAC,et al.An AIE probe for long-term plasma membraneimaging and membrane-targeted photodynamic therapy [J].Chinese ChemicalLetters,2023,34(4).
[0102]
[11] PHAM T C,NGUYEN V N,CHOI Y,et al.Recent Strategies to DevelopInnovative Photosensitizers for Enhanced Photodynamic Therapy[J].Chem Rev,2021,121(21):13454-619.
[0103]
[12] GOURDON L,CARIOU K,GASSER G.Phototherapeutic anticancerstrategies with first-row transition metal complexes:a critical review[J].Chem Soc Rev,2022,51(3):1167-95.
[0104]
[13] LI X,YANG M,CAO J,et al.H-Aggregates of Prodrug-HemicyanineConjugate for Enhanced Photothermal Therapy and Sequential Hypoxia-ActivatedChemotherapy[J].ACS Materials Letters,2022,4(4):724-32.
[0105]
[14] CHEN W,WANG Z,TIAN M,et al.Integration of TADF Photosensitizeras"Electron Pump"and BSA as"Electron Reservoir"for Boosting Type IPhotodynamic Therapy[J].J Am Chem Soc,2023,145(14):8130-40.
[0106]
[15] HU W,PRASAD P N,HUANG W.Manipulating the Dynamics of Dark ExcitedStates in Organic Materials for Phototheranostics[J].Acc Chem Res,2021,54(3):697-706.
[0107]
[16] LI H,KIM Y,JUNG H,et al.Near-infrared(NIR)fluorescence-emittingsmall organic molecules for cancer imaging and therapy[J].Chem Soc Rev,2022,51(21):8957-9008.
[0108]
[17] ZLITNI A,GOWRISHANKAR G,STEINBERG I,et al.Maltotriose-basedprobes for fluorescence and photoacoustic imaging of bacterial infections[J].Nature communications,2020,11(1):1250.
[0109]
[18] HUANG Y,CHEN W,CHUNG J,et al.Recent progress in fluorescentprobes for bacteria[J].Chem Soc Rev,2021,50(13):7725-44.
[0110]
[19] DEFRES S,MARWICK C,NATHWANI D.MRSAas a cause of lung infectionincluding airway infection,community-acquired pneumonia and hospital-acquiredpneumonia[J].The European respiratory journal,2009,34(6):1470-6.
[0111]
[20] KNOX H J,CHAN J.Acoustogenic Probes:ANew Frontier inPhotoacoustic Imaging[J].Acc Chem Res,2018,51(11):2897-905.
[0112]
[21] LIU Y,TENG L,YIN B,et al.Chemical Design of ActivatablePhotoacoustic Probes for Precise Biomedical Applications[J].Chem Rev,2022,122(6):6850-918.
[0113]
[22] LI L,HAN X,WANG M,et al.Recent advances in the development ofnear-infrared organic photothermal agents[J].Chemical Engineering Journal,2021,417.
[0114]
[23] LIU Y,BHATTARAI P,DAI Z,et al.Photothermal therapy andphotoacoustic imaging via nanotheranostics in fighting cancer[J].Chem SocRev,2019,48(7):2053-108.
[0115]
[24] VICKERMAN B M,ZYWOT E M,TARRANT T K,et al.Takingphototherapeutics from concept to clinical launch[J].Nat Rev Chem,2021,5(11):816-34.
[0116]
[25] ZHAO X,LIU J,FAN J,et al.Recent progress in photosensitizers forovercoming the challenges of photodynamic therapy:from molecular design toapplication[J].Chem Soc Rev,2021,50(6):4185-219.
[0117]
[26] LUO S,TAN X,FANG S,et al.Mitochondria-Targeted Small-MoleculeFluorophores for Dual Modal Cancer Phototherapy [J].Advanced FunctionalMaterials,2016,26(17):2826-35.
[0120]
[27] XU Z,ZHANG M-X,XU Y,et al.The visualization of lysosomal andmitochondrial glutathione via near-infrared fluorophore and in vivo imagingapplication[J].Sensors and Actuators B:Chemical,2019,290:676-83.
[0124]
[28] ZOU Y,LI M,XIONG T,et al.ASingle Molecule Drug TargetingPhotosensitizer for Enhanced Breast Cancer Photothermal Therapy [J].Small,2020,16(18):e1907677。
Claims
1. A compound represented by formula II or a pharmaceutically acceptable salt thereof: R 1 independently selected from hydrogen atoms and R 2 Independently selected from hydroxyl, and X is independently selected from O, S, and Se.
2. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, It is characterized in that The compound is selected from:
3. Use of the compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof in the preparation of a photosensitizer.
4. Use of the compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof in the preparation of photoacoustic imaging and therapeutic drugs for prostate cancer at the in vitro, cellular or in vivo levels.
5. Use of the compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof in the preparation of in vitro, cellular or in vivo photoacoustic imaging of pneumonia induced by bacteria in situ and in vivo tumor-homing bacteria.
6. The use according to claim 5, It is characterized in that The bacterium is Staphylococcus aureus.
7. A method for preparing a compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof, It is characterized in that Its preparation method is: Where: R 1 ,R 2 , X is defined as any one of claims 1 to 4; (1) adding 4-(Boc-amino)phenol or p-aminothiophenol or 4,4'-diselenanediyldiphenylamine, compound 1, base and solvent to a round-bottom flask, reacting at a set temperature and under stirring conditions, after the reaction is completed, extracting the reaction solution, concentrating under reduced pressure and purifying to obtain I or further reacting with p-nitrobenzyl chloroformate, base and solvent under argon protection under anhydrous conditions at room temperature, extracting the reaction solution after the reaction is completed, concentrating under reduced pressure and purifying to obtain I; (2) adding I prepared in step (1), a condensing agent, a base, a ligand and a solvent to a round-bottom flask, reacting at room temperature under argon protection and anhydrous conditions, extracting the reaction solution after the reaction is completed, concentrating and purifying under reduced pressure, and then reacting with trifluoroacetic acid at room temperature, concentrating and purifying under reduced pressure to obtain II; or reacting I prepared in step (1) with di-tert-butyl dicarbonate, a base and a solvent under argon protection and anhydrous conditions at room temperature, extracting the reaction solution after the reaction is completed, concentrating and purifying under reduced pressure, and then reacting the obtained compound with a condensing agent, a base, a ligand and a solvent under argon protection and anhydrous conditions at room temperature, extracting the reaction solution after the reaction is completed, concentrating and purifying under reduced pressure, and then reacting with trifluoroacetic acid at room temperature, concentrating and purifying under reduced pressure to obtain II.
Citation Information
Patent Citations
Ultra-sensitive fluorescent probe for detecting nitroreductase in bacteria and application of ultra-sensitive fluorescent probe in bacterial infection
CN112694431A
Targeted fluorescent probe for two prostate-specific membrane antigens as well as preparation method and application of targeted fluorescent probe
CN113979912A
Near-infrared cyanine probe for detecting penicillin G acylase as well as preparation method and application of near-infrared cyanine probe
CN120463759A
compound for detection of biothiol and Method for manufacturing thereof
KR1020180001625A
